WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

BARCELONA, Spain, Sept. 17, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.

Pioneering Advances in mRNA Therapeutics

WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and the US, demonstrated exceptional safety, immunogenicity, and anti-tumor activity in the latest clinical trials. The vaccine is being developed specifically for adult patients with advanced EBV-positive solid tumours and refractory or relapsed EBV-positive lymphomas, diseases for which there are currently no effective, low-toxicity treatment options.

Impressive Clinical Performance Recognized by ESMO

Interim clinical data presented at ESMO 2024 highlighted the vaccine's ability to activate the patient's immune system, leading to the production of cytotoxic T cells, antigen-specific antibodies and memory T cells that target and destroy cancer cells. This novel mechanism offers a promising alternative to conventional CAR-T and monoclonal antibody therapies and also aims to prevent tumor recurrence, providing a triple benefit, particularly for patients with late-stage nasopharyngeal carcinoma and NK/T cell lymphoma.

Innovative Technology and Global Impact

WGc-043 is a testament to WestGene's proprietary mRNA platform, which includes cutting-edge innovations in mRNA sequence design, novel lipid nanoparticle (LNP) delivery systems, and scalable manufacturing processes. The vaccine was developed using WestGene's patented LNP technology, which is recognized for its superior efficacy and safety. This technology has been instrumental in overcoming the challenges associated with mRNA vaccine delivery and has positioned WestGene as a leader in the global mRNA therapeutic

Expanding Horizons in Cancer Treatment

The global market for mRNA cancer vaccines is expected to grow significantly, with estimates ranging from $230 billion to $300 billion by 2035. The success of WGc-043 at ESMO underscores the potential of mRNA technology not only to lead the field, but also to accelerate clinical development and provide safe, effective treatments for late-stage cancer patients.

Looking Ahead

WestGene Biopharma (www.westgenepharma.com) remains committed to advancing its mRNA platform and expanding its pipeline to address unmet medical needs across a range of indications. The company's innovative approach and commitment to collaboration will continue to drive progress in the field of mRNA therapeutics and bring hope to patients worldwide.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

JILIN, China, Dec. 22, 2024 /PRNewswire/ -- On December 19, the Second World Ice and Snow Economy of Cold Regions Conference opened at BEIDAU SKI RESORT in Jilin City.

Hu Yuting first extended welcome on behalf of the Jilin Provincial Party Committee and the provincial government to the guests attending the event and expressed gratitude to friends from all walks of life who care about and support the revitalization and development of Jilin. He said that the ice and snow economy is an important engine for economic development in cold regions. This conference, with the theme of PROSPER THE ICE AND SNOW ECONOMY, JOIN HANDS FOR A WIN-WIN FUTURE, builds a new international exchange platform, innovates new carriers for industrial cooperation, and expands new scenarios for ice and snow consumption, which is of great significance for stimulating the vitality of the ice and snow economy in cold regions. With a high-quality product matrix, we promote leapfrog development of ice and snow tourism. With the unique advantages of powder snow, forest sea, rime, and hot springs and the brand matrix of Snow all over Changbai Mountain, and with an attitude of opening the door to welcome guests and treating guests from all directions, we warmly welcome domestic and foreign tourists. People at home and abroad are welcome to experience Jilin's ice and snow. We will provide warm-hearted services to make tourists come happily and return satisfied.

We are willing to share development opportunities with friends from all over the world. Focusing on fields such as refining ice and snow tourism, developing ice and snow equipment, promoting ice and snow consumption, prospering ice and snow culture, and popularizing ice and snow sports, we promote all parties to deepen cooperation, complement each other's advantages, and achieve mutual benefit and win-win results, and jointly explore new opportunities for the development of the ice and snow industry.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

The opening ceremony of the 2nd World Ice and Snow Economy of Cold Regions Conference

The opening ceremony of the 2nd World Ice and Snow Economy of Cold Regions Conference